Loading Aurobindo Pharma…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 9,106 | 8,752 | 8,605 | 7,792 | 8,381 |
| Operating profit | 1,394 | 1,322 | 1,309 | 1,198 | 1,347 |
| Operating margin | 15.3% | 15.1% | 15.2% | 15.4% | 16.1% |
| Net profit | 1,033 | 921 | 910 | 825 | 903 |
| Net margin | 11.3% | 10.5% | 10.6% | 10.6% | 10.8% |
| EPS (₹) | 17.86 | 15.86 | 15.67 | 14.20 | 15.56 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 33,385 | 31,378 | 28,705 | 24,617 |
| Operating profit | 5,193 | 5,048 | 4,442 | 2,538 |
| Operating margin | 15.6% | 16.1% | 15.5% | 10.3% |
| Net profit | 3,505 | 3,486 | 3,173 | 1,928 |
| Net margin | 10.5% | 11.1% | 11.1% | 7.8% |
| EPS (₹) | 60.34 | 59.81 | 54.16 | 32.90 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 58,502 | 49,785 | 45,072 | 39,890 |
| Total liabilities | 20,619 | 17,138 | 15,221 | 13,038 |
| Shareholders’ equity | 37,891 | 32,653 | 29,843 | 26,840 |
| Total debt | 8,073 | 8,263 | 6,648 | 5,286 |
| Cash & equivalents | 7,191 | 5,569 | 3,393 | 4,396 |
| Debt / equity | 0.21 | 0.25 | 0.22 | 0.20 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | 5,526 | 3,925 | 2,435 | 2,387 |
| Capital expenditure | -3,105 | -2,520 | -3,562 | -2,720 |
| Free cash flow | 2,422 | 1,405 | -1,127 | -334 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | 9.2% | 10.7% | 10.6% | 7.2% |
| Return on assets | 6.0% | 7.0% | 7.0% | 4.8% |
| Net margin | 10.5% | 11.1% | 11.1% | 7.8% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for AUROPHARMA. Finnhub coverage is limited for some India-listed stocks.